De-risking pharmaceutical development with high-quality information
Addressing unanticipated problems with a drug candidate can be very expensive, especially if the candidate reaches clinical trials before the problem is discovered. The solution is to identify all potential risks with regard to safety, efficacy and synthesis in the early stages of discovery and kill projects that do not adequately meet advancement criteria. What is the best way to achieve this?
This white paper looks at the potential of data-driven drug development as practiced by major players in the global pharmaceutical industry. It also presents the principles of good data stewardship in terms of early drug development workflows, focusing on:
- The meaning of comprehensive and accurate data
- Essential data organization traits needed to support discoverability
- What information providers can do to ensure ease of data retrieval